Clovis Oncology, Inc.Find Ratings Reports
CLOVIS ONCOLOGY INC's gross profit margin for the third quarter of its fiscal year 2020 is essentially unchanged when compared to the same period a year ago. The company has grown sales and net income during the past quarter when compared with the same quarter a year ago, however, it was unable to keep up with the growth of the average competitor within its subsector. CLOVIS ONCOLOGY INC is extremely liquid. Currently, the Quick Ratio is 2.05 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 86.71% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY20||Q3 FY19|
|Net Sales ($mil)||38.77||37.6|
|Net Income ($mil)||-78.68||-94.07|
|Balance Sheet||Q3 FY20||Q3 FY19|
|Cash & Equiv. ($mil)||224.7||354.1|
|Total Assets ($mil)||593.06||716.89|
|Total Debt ($mil)||635.01||696.27|
|Profitability||Q3 FY20||Q3 FY19|
|Gross Profit Margin||79.98||80.72|
|Return on Assets||-62.34||-55.82|
|Return on Equity||0.0||0.0|
|Debt||Q3 FY20||Q3 FY19|
|Share Data||Q3 FY20||Q3 FY19|
|Shares outstanding (mil)||88.31||54.81|
|Div / share||0.0||0.0|
|Book value / share||-1.85||-1.6|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||4763909.0||4683424.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the subsector average, indicating a discount.
|CLVS NM||Peers 32.89||CLVS NM||Peers 87.81|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CLVS's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CLVS's P/CF is negative making the measure meaningless.
|CLVS NM||Peers 21.08||CLVS NA||Peers 0.69|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CLVS's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CLVS NM||Peers 11.24||CLVS 30.14||Peers 10.80|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CLVS's P/B is negative making this valuation measure meaningless.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CLVS is expected to have an earnings growth rate that significantly exceeds its peers.
|CLVS 2.74||Peers 1710.59||CLVS 19.75||Peers 695.47|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CLVS is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
CLVS significantly trails its peers on the basis of sales growth.